ArticleJournal of ginseng research2026
A combined extract of
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke remains a major cause of mortality and disability, with few therapeutic options outside the narrow time window for reperfusion. Collateral circulation critically sustains penumbral viability, yet no pharmacological agent is approved to enhance collateral flow. Methods: A combined extract of Results: Pre-ischemic SM/PN (15-60 mg/kg) significantly reduced cortical infarct volume and sustained ACA perfusion during the first 15 min after occlusion without increasing VEGF in brain or endothelial cells. SM/PN decreased Iba-1 immunoreactivity in peri-infarct regions and suppressed inducible nitric oxide synthase, interleukin-6, and tumor necrosis factor-α in lipopolysaccharide-stimulated BV2 microglia. It also reduced endothelial PECAM-1 upregulation while restoring occludin and partially recovering claudin-5, accompanied by reduced phosphorylation of STAT3 and p38. Conclusions: SM/PN provides early neurovascular protection through non-angiogenic collateral enhancement, microglial modulation, and blood-brain barrier stabilization. This integrated mechanism distinguishes SM/PN from conventional pro-collateral or angiogenic strategies and supports its potential as an adjunctive therapy for acute ischemic stroke, especially for patients who cannot undergo reperfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.